Does the dose matter?

Clinical Infectious Diseases

Volumn 33, Issue SUPPL. 3, 2001, Pages

  Craig, W A ^a  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CONFERENCE PAPER; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS;

EID: 0035885054     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/321854     Document Type: Conference Paper

References (30)

1. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
2. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections
3. Correlation antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
4. Comparative antibiotic dose-effect relationships at several dosing intervals in murine pneumonitis and thigh-infection models
5. Postantibiotic effects and the dosing of macrolides, azalides, and streptogramins
6. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection
7. Interrelationships between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins
8. Pharmacodynamics of fluoroquinolones in experimental animals
9. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models
10. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: Application to breakpoint determination
11. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae
12. Pharmacodynamics of gemifloxacin (GEM) against quinolone-resistant strains of S. pneumoniae (SP) with known resistance mechanisms
13. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
14. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the drug-resistant Streptococcus pneumoniae therapeutic working group
15. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children
16. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media
17. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
18. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
19. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneurnoniae
20. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
21. Three levofloxacin treatment failures of pneumococcal respiratory tract infections
22. Development of resistance during antimicrobial therapy: A review of antibiotic class and patient characteristics in 173 studies
23. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
24. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo
25. Pharmacodynamics of ceftriaxone against cephalosporin-sensitive and -resistant Enterobacter cloacae in vivo
26. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
27. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis
28. Evaluation of intravenous ciprofioxacin in patients with nosocomial lower respiratory tract infections
29. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus
30. Mutation prevention concentration of moxifloxacin and levofloxacin against clinical isolates of S. pneumoniae and S. aureus